Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

913 results about "Ocular disease" patented technology

Methods of treating active and chronic thyroid eye disease

Methods of treating patients with chronic thyroid eye disease are provided for herein, such as by administering antibodies and compositions that bind to and / or antagonize IGF-1R.
Owner:VIRIDIAN THERAPEUTICS INC

Bioresorbable ocular drug delivery device

Disclosed herein are implantable intraocular drug delivery devices structured to provide targeted and / or controlled release of a drug to a desired intraocular target tissue, and methods of implanting and methods of using such devices for the treatment of ocular diseases and disorders. In certain embodiments, some, most, or essentially all of the device is made of biodegradable materials.
Owner:GLAUKOS CORP

Cellular reprogramming to reverse aging and promote organ and tissue regeneration

ActiveUS12274733B2Senses disorderNervous disorderTissue repairVaccine virus
Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a (e.g., ocular disease), preventing a disease (e.g., ocular disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof).
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE

Multimodal data collection and diagnosis of rare ocular diseases

The present disclosure relates to diagnosis of ocular diseases by leveraging an attention-based multimodal graphical neural network (AM-GNN) based on multimodal data that includes one or more image-text pairs. Each image of the image-text pair may depict a retinal scan of a subject that may correspond to one or more imaging modalities. A multimodal dataset may be collected from different imaging modalities by data crawling to automatically collect relevant data for the targeted diseases from identified sources. In some aspects, a concept bank, comprising concepts or terminologies associated with the targeted diseases, may be provided to the AM-GNN to generate a multimodal graph. The AM-GNN may be configured to find an association between a set of nodes including image-text pairs, a set of diseases, and the concepts using an attention mechanism. Based on the multimodal graph, an output may be generated, including a predicted disease and related concept(s).
Owner:OPTAIN HEALTH INC

Ophthalmic atrophy arc image segmentation method based on full supervision

The invention discloses an optic disk atrophy arc image segmentation method based on full supervision, and particularly relates to the technical field of medical equipment, and the method comprises the following steps: S1, multi-scale feature extraction, S2, local-global feature enhancement, S3, adaptive feature fusion, S4, gradient flow optimization, S5, mixing of a loss function, and S6, data enhancement and generalization optimization. According to the method, the long-range dependence of the optic disk and the atrophic arc is globally modeled through the PVTv2 encoder, the detail segmentation precision of the optic disk atrophic arc at the blood vessel crossing and fuzzy boundary is remarkably improved in combination with the multi-scale attention and dilated convolution of the feature enhancement module, cross-level feature fusion is realized with linear complexity based on the Mama decoder, and the accuracy of feature fusion is improved. Efficiency and structure coherence are considered; the weight is balanced by the mixed loss function, and early lesion missing detection is reduced; a data enhancement and residual module enhances the generalization ability of the model, and a high-precision and efficient quantitative analysis tool is integrally provided for early screening of blind eye diseases such as pathological myopia and glaucoma.
Owner:CENT SOUTH UNIV

TSHR antagonist compound, pharmaceutical composition, and preparation method therefor and use thereof

Provided in the present invention are a TSHR antagonist compound, a pharmaceutical composition, and a preparation method therefor and the use thereof. The compound has good TSHR antagonism, and is used in the treatment of thyroid-associated conditions and / or diseases, such as hyperthyroidism, Graves' disease, Graves' ophthalmopathy, and thyroid eye disease, and in the preparation of a drug for treating such conditions or diseases.
Owner:CHANGCHUN GENESCIENCE PHARM CO LTD

ITGB1-siRNA lipid nanoparticle and application of ITGB1-siRNA lipid nanoparticle in anti-angiogenesis treatment

The invention belongs to the technical field of biological medicine and molecular biology, and particularly relates to ITGB1-siRNA lipid nanoparticles and application of the ITGB1-siRNA lipid nanoparticles in anti-angiogenesis treatment. Specifically, the ITGB1-siRNA lipid nanoparticles are successfully prepared, the lipid nanoparticles are loaded with integrin beta1 small interfering RNA (ITGB1-siRNA), are modified with triptolide (TP) and are coupled with anti-Flt1 peptide, so that the lipid nanoparticles can target vascular endothelial cells (VEC) and pericytes of CNV, and a good treatment effect on the CNV is achieved. Therefore, the lipid nanoparticles researched and developed by the invention are expected to become a new choice for treating the CNV-related eye diseases, and have good practical application value.
Owner:SHANDONG FIRST MEDICAL UNIVERSITY FIRST AFFILIATED HOSPITAL (QIANFO MOUNTAIN HOSPITAL OF SHANDONG PROVINCE)

Cellular reprogramming to reverse aging and promote organ and tissue regeneration

Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a (e.g., ocular disease), preventing a disease (e.g., ocular disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof).
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE

Homocysteine as Graves eye disease biomarker and application thereof

The invention discloses homocysteine as a Graves eye disease biomarker and application thereof, the biomarker is homocysteine (Hcy), application of a reagent for detecting the biomarker in preparation of a product for diagnosing Graves eye diseases, and the reagent is used for detecting the level of Hcy in sample serum. By detecting the level of homocysteine (Hcy) in serum, an objective and quantitative biomarker is provided for diagnosis of Graves eye diseases (GO), the diagnosis accuracy is remarkably improved, and the defects that existing clinical activity scores are high in subjectivity and insensitive to latent patients are overcome; the Hcy level is in positive correlation with GO activity, and can be used for monitoring disease progression and treatment effect, optimizing disease management, reducing serious complications and improving life quality of patients.
Owner:BEIJING TONGREN HOSPITAL AFFILIATED TO CAPITAL MEDICAL UNIV

Ocular disease marker identification using multi-spectral imaging

A method and system for the use of multi-spectral retinal images to achieve an effective, efficient, and AI enabled automated retinal disease biomarker detection using biomarker identification, segmentation, and quantification. A plurality of digital multi-spectral images of a retina of a patient at a plurality of illumination wavelengths can be done using a multi-spectral ophthalmoscope. The images can then be registered, processed, and assessed to automatically quantifying one or more biomarker based on the location and size of the biomarker in the plurality of processed multi-spectral images.
Owner:AI-SPECTRAL TECHNOLOGY CORP

Cellular reprogramming to reverse aging and promote organ and tissue regeneration

Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a (e.g., ocular disease), preventing a disease (e.g., ocular disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof).
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE

Visual conversion system, method and equipment for auxiliary diagnosis of eye diseases and storage medium

The invention discloses a visual conversion system, method and equipment for eye disease auxiliary diagnosis and a storage medium, and solves the problems of single function, high data dependence, large computing resource demand and weak interpretability in the field of eye disease auxiliary diagnosis in the prior art. The system comprises an input processing module, a visual transformer trunk, a hybrid expert layer, a decoder head and an output generation module. According to the visual conversion system for eye disease auxiliary diagnosis, various ophthalmology imaging modes can be processed, multiple tasks can be executed, and the input processing module, the visual transformer trunk, the mixed expert layer, the decoder head and the output generation module in the system cooperate to reduce calculation requirements and maintain accuracy at the same time; the expert is dynamically selected according to the complexity of the input image, it is ensured that different inputs can obtain optimal feature processing, accuracy and efficiency are both considered, a decoder structure can be customized according to the features of different tasks, and the output precision of each task is ensured.
Owner:南通诺瞳奕目医疗科技有限公司 +1

Multi-modal ophthalmic imaging system and method for imaging eye of patient

The invention relates to a multi-modal ophthalmic imaging system and method for imaging an eye of a patient. A multi-modality ophthalmic imaging system for acquiring an ophthalmic image of a patient's eye includes a first imaging module operable in a first imaging modality for acquiring a first ophthalmic image of a first portion of the patient's eye and one or more further imaging modules operable in a second imaging modality for acquiring a second ophthalmic image of a second portion of the patient's eye. The one or more further imaging modules are each operable in a different imaging modality. The imaging system further comprises a control module arranged to detect an anomaly in the first ophthalmic image indicative of an ocular disease, determine a region of interest in the eye of the patient based on the detected anomaly, where the region of interest is a region within the eye of the patient predicted to contain a second anomaly, and determine a region of interest in the eye of the patient based on the detected anomaly. And determining a second imaging modality for imaging the determined region of interest based on the second anomaly, and controlling the selected second imaging module to acquire a second ophthalmic image of the determined region of interest.
Owner:OPTOS PLC

Pharmaceutical composition comprising 3,4-dihydroquinolin-2(1H)-one compound

To provide a pharmaceutical composition comprising a novel compound which has a thyroid-stimulating hormone receptor antagonist activity and is useful for the treatment of thyroid-related diseases.SOLUTION: There is provided a pharmaceutical composition comprising a 3,4-dihydroquinolin-2(1H)-one compound represented by a formula (I) or a pharmacologically acceptable salt thereof. A pharmaceutical composition comprising the compound or the pharmacologically acceptable salt thereof has an antagonist activity against thyroid-stimulating hormone receptors and is useful as a therapeutic agent or the like for thyroid-related diseases (for example, hyperthyroidism, Graves' disease, thyroid eye disease and thyroid cancer).SELECTED DRAWING: None
Owner:KISSEI PHARMACEUTICAL CO LTD

Formulations and methods for treating conditions of the eye

The present disclosure relates to methods of treating chronic conditions of the eye, such as dry eye disease and blepharitis, as well as to methods for increasing secretion of meibum. This disclosure also relates to formulations suitable for treating chronic conditions of the eye such as dry eye disease and blepharitis.
Owner:SIGHT SCIENCES INC

Double stranded oligonucleotide for modulating JAK1 expression

The present invention relates to double stranded oligonucleotides that are complementary to JAK1, leading to modulation of the expression of JAK1. Modulation of JAK1 expression is beneficial for a range of medical disorders including inflammatory bowel disease, organ transplant rejection, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriasis, dermatitis, diabetic nephropathy, systemic lupus erythematosus (SLE), dry eye disease, cancer, myelofibrosis, and asthma. Also included are compositions comprising the double stranded oligonucleotide and methods of treatment using the double stranded oligonucleotide.
Owner:F HOFFMANN LA ROCHE & CO AG +1

Topical ophthalmological compositions

ActiveUS12485177B2BiocideSenses disorderTG - TriglycerideParaffinum Perliquidum
A topical ophthalmological composition includes a muscarinic receptor antagonist as an active pharmaceutical ingredient; and medium chain triglycerides (MCTs) or light liquid paraffin oil as liquid vehicle. The topical ophthalmological composition treats an ocular disease.
Owner:ADS THERAPEUTICS LLC

Ophthalmic formulation for preventing and / or treating cataracts by eye drop administration

An ophthalmic formulation for preventing and treating cataracts contains an active substance for treating eye diseases and a pharmaceutically acceptable carrier or excipient. The active substance is oxidized cholesterol, including lanosterol or 25-hydroxycholesterol; the pharmaceutically acceptable carrier or excipient contains a surfactant, a tackifier, a cosolvent, and a solvent; the content of the oxidized cholesterol in the formulation is 0.01-5 mg / mL; and the mass ratio of the surfactant, the tackifier, the cosolvent, and the oxidized cholesterol is (1-300):(1-100):(100-3000):1, with the balance being the solvent. Upon eye drop administration, the formulation can cause the active substance to be selectively enriched in the lens of a laboratory animal to accurately exert the effect of treating cataracts. The active substance is not distributed in the aqueous humor and the vitreous body, thereby avoiding toxic and side effects on other eye tissue and the whole body.
Owner:CHENGDU RUIMU BIO PHARM TECH CO LTD

Compositions and methods of treating ocular diseases

The present disclosure provides recombinant adeno-associated virus (AAV) virions with altered capsid protein, where the recombinant AAV (rAAV) virions exhibit greater ability to cross barriers between intravitreal fluid and retinal cells, and thus greater infectivity of a retinal cell compared to wild-type AAV, and where the rAAV virions comprise a heterologous nucleic acid. The present disclosure provides methods of delivering a gene product to a retinal cell in an individual.
Owner:RGT UNIV OF CALIFORNIA

(R)-3-(3-chloro-5-fluoro-2-((4-(1h-pyrazol-1-yl)-2-methylquinolin-8-yloxy)methyl)phenyl)morpholine derivatives and related compounds as bradykinin (BK) B2 receptor antagonist for treating skin diseases

The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to said compound(s) for use as in a method of treating a skin disorder; eye disease; ear disease; mouth, throat and respiratory disease; gastrointestinal disease; liver, gallbladder and pancreatic disease; urinary tract and kidney disease; disease of male genitale organs and female genitale organs; disease of the hormone system; metabolic disease; cardiovascular disease; blood disease; lymphatic disease; disorder of the central nervous system; brain disorder; musculoskeletal system disease; allergy disorder; pain; infectious disease; inflammatory disorder; injury; immunology disorder; cancer; hereditary disease; or edema.
Owner:PHARVARIS GMBH

Nano drug delivery system for treating neovascular eye diseases and preparation method thereof

The invention belongs to the technical field of nano-drugs, and discloses a multifunctional nano-drug delivery system for treating neovascular eye diseases and a preparation method of the multifunctional nano-drug delivery system. The nano drug delivery system disclosed by the invention is a composite nano preparation which takes dendritic mesoporous silica nanoparticles as a carrier and co-loads cerium zirconium oxide nano enzyme and an anti-VEGF (vascular endothelial growth factor) drug, various active oxygen can be efficiently removed, oxygen is continuously released through catalytic decomposition of hydrogen peroxide, a retina hypoxia microenvironment is improved, and the retina hypoxia effect is improved. According to the present invention, the anti-VEGF drug delivery system can reduce the oxidative stress induced retinal pigment epithelial cell apoptosis rate, reduce the inflammatory reaction, and simultaneously achieve the slow release and the controlled release of the anti-VEGF drug, and the drug effect maintenance time can achieve more than 60 days, such that the multi-target synergistic treatment can be achieved through the synergistic regulation of the multiple pathological links such as oxygen deficit-oxidative stress-inflammation-angiogenesis, and the anti-VEGF drug delivery effect can be achieved. The choroidal neovascularization can be effectively inhibited by single intravitreal injection, and a new strategy of multi-target collaborative treatment is provided for neovascular macular degeneration and other eye diseases.
Owner:SHANGHAI UNIV

Ophthalmology AI intelligent ward control system and method based on voice interaction

The invention discloses an ophthalmology AI intelligent ward control system and method based on voice interaction. The system comprises an anti-noise voice acquisition unit, a multi-modal identity verification unit, a specialized semantic analysis unit, a medical rule engine unit, a safety protection unit, a multi-modal feedback unit and a dynamic optimization unit. Medical equipment noise is filtered out through a microphone array and an adaptive beam forming technology, and an instruction is analyzed in combination with a dialect recognition engine; executing triple identity verification, and performing forced superposition authentication on the cognitive impairment patient; calling an ophthalmology knowledge base to identify the risk keyword and generate a structured instruction; dynamically regulating and controlling the environment according to the eye disease type, and intercepting violation settlement according to a medical insurance rule; precise equipment voice control is forbidden, and when an emergency keyword is triggered, an OCT image is pushed preferentially and is directly connected with a physician; a big-character highlight interface and tactile pulse feedback are provided for the visually impaired patient, and data are synchronized to the HIS system in real time; and the dynamic optimization unit continuously updates the knowledge base and the medical insurance model. According to the invention, the instruction identification precision, the medical safety and the service suitability of the ophthalmology ward are obviously improved.
Owner:NANCHANG AIER EYE HOSPITAL CO LTD

Integrin targeting ligands for ocular delivery of rnai compounds

PendingUS20240409927A1Organic active ingredientsSenses disorderDiseaseIntegrin targeting
The disclosure relates to RNA agents modified for targeted delivery to the eye. The present invention provides modified double stranded ribonucleic acid (dsRNAi) agents conjugated to an integrin targeting ligand, as well as methods of modulating the expression of a target gene in an ocular cell or tissue and methods of treating subjects having an ocular disease or disorder using such dsRNAi agents.
Owner:ALNYLAM PHARMACEUTICALS INC

Gene therapy for treating an ocular disease

Provided herein are gene therapy methods for the treatment of diseases or disorders associated with the eye of a subject involving the use of recombinant adeno-associated viruses (rAAVs) comprising a variant AAV capsid to deliver a transgene to the eye of the subject. Also provided herein are rAAVs and compositions comprising the rAAVs that can be used in the gene therapy methods of the disclosure, and methods of making such rAAVs.
Owner:REGENXBIO INC